GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alk-Abello AS (LTS:0OIR) » Definitions » Research & Development

Alk-Abello AS (LTS:0OIR) Research & Development : kr555 Mil (TTM As of Jun. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Alk-Abello AS Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Alk-Abello AS's Research & Development for the three months ended in Jun. 2024 was kr125 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2024 was kr555 Mil.

Alk-Abello AS Research & Development Historical Data

The historical data trend for Alk-Abello AS's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alk-Abello AS Research & Development Chart

Alk-Abello AS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 466.00 515.00 631.00 665.00 618.00

Alk-Abello AS Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 160.00 149.00 151.00 130.00 125.00

Alk-Abello AS Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr555 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alk-Abello AS  (LTS:0OIR) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Alk-Abello AS Research & Development Related Terms

Thank you for viewing the detailed overview of Alk-Abello AS's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Alk-Abello AS Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alk-Abello AS (LTS:0OIR) » Definitions » Research & Development
Comparable Companies
OCSE:ZEAL OCSE:BAVA OCSE:GUBRA OCSE:PEG OCSE:GMAB OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 MRNA XKRX:068270 XBRU:ARGX XBRU:UCB BNTX ALNY BGNE BMRN SZSE:300122 RPRX
Traded in Other Exchanges
AKBLF:USA ALK B:Denmark 4AJ0:Germany
Address
Boge Alle 6-8, Horsholm, DNK, DK-2970
Website
https://www.alk.net
Alk-Abello A/S is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication.

Alk-Abello AS Headlines

No Headlines